First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

This first-in-human study is testing a new drug called PLX-61639 in patients with advanced solid tumors that have a specific genetic change called a SMARCA4 loss-of-function mutation — a change that makes cancer cells rely on a related protein called SMARCA2 to survive. **You may be eligible if...** - You have a locally advanced or metastatic solid tumor with a confirmed SMARCA4 loss-of-function mutation - Your cancer has progressed on or you could not tolerate all available approved treatments - You have measurable disease on imaging scans - Your general health score (ECOG) is 0 or 1 (fully active or restricted in strenuous activity only) - Your liver, kidneys, bone marrow, and heart function are adequate **You may NOT be eligible if...** - You have a germline (inherited) SMARCA4 mutation or a known SMARCA2 mutation - Your cancer has spread to the brain and is causing symptoms - You have received prior SMARCA2-directed therapy - You have a history of other cancers, significant heart disease, uncontrolled high blood pressure, or a prolonged QT interval on ECG Talk to your doctor to see if this trial is right for you.